Analyst Price Targets — PRLD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 10, 2024 6:43 am | Robert Burns | H.C. Wainwright | $5.00 | $5.17 | StreetInsider | H.C. Wainwright Reiterates Neutral Rating on Prelude Therapeutics (PRLD) |
| June 20, 2024 5:33 am | Peter Lawson | Barclays | $3.00 | $3.87 | TheFly | Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays |
| March 13, 2024 2:51 am | Reni Benjamin | JMP Securities | $7.00 | $4.62 | StreetInsider | JMP Securities Starts Prelude Therapeutics (PRLD) at Market Outperform, 'Precision Targeting of SMARCA Drives Cell Kill' |
| November 17, 2022 6:12 am | — | H.C. Wainwright | $15.00 | $7.70 | Benzinga | HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15 |
| November 15, 2022 8:41 am | — | Morgan Stanley | $10.00 | $8.10 | Benzinga | Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $10 |
Latest News for PRLD
WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026.
Aptorum Group (NASDAQ: APM - Get Free Report) and Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Risk and Volatility Aptorum Group has a
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company's oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17-22.
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for…
WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRLD.
U.S. House Trading
No House trades found for PRLD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.